drugset / Trial / NCT06033261
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to generate safety and immunogenicity data and establish a proof-of-concept of clinical benefit of the mRNA-1608 vaccine candidate.
Timeline
- Start
- 2023-09-06
- Primary completion
- 2025-04-25
- Completion
- 2025-04-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bexsero | Vaccine | — | — |
| Subject | mRNA-1608 | Unknown | — | Intramuscular |